472-26-4
Chemical Structure
Telocinobufagin
Synonym(s): Telobufotoxin; Telocinobufogenin
- CAS No.: 472-26-4
- Formula:C24H34O5
- Molecular Weight:402.52
IUPAC Name: 5-((3S,5S,8R,9S,10R,13R,14S,17R)-3,5,14-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2H-pyran-2-one
InChIKey: PBSOJKPTQWWJJD-ZBDZJSKLSA-N
SMILES: O[C@@]([C@@]1(CC2)C)(CC[C@@H]1C(C=C3)=COC3=O)[C@@](CC[C@@]45O)([H])[C@@]2([H])[C@]4(CC[C@H](O)C5)C
Biological Activity: Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail and PLK1 pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na+/K+-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models[1][2][3][4][5][6][7][8][9].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Telocinobufagin | 99.50% | Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail and PLK1 pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na+/K+-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Shen Y, et al. Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling. J Nat Prod. 2022 Apr 22;85(4):765-775. [Content Brief]
- [2]. Ma X, et al. Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the JAK2/STAT3 signaling pathway. Eur J Pharmacol. 2023 Mar 5;942:175529. [Content Brief]
- [3]. Wu SC, et al. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Int Immunopharmacol. 2015 Apr;25(2):353-62. [Content Brief]
- [4]. Feitosa GIMC,et al. Potent nonopioid antinociceptive activity of telocinobufagin in models of acute pain in mice. Pain Rep. 2019 Oct 8;4(6):e791. [Content Brief]
- [5]. Kennedy DJ, et al. Telocinobufagin, a Novel Cardiotonic Steroid, Promotes Renal Fibrosis via Na⁺/K⁺-ATPase Profibrotic Signaling Pathways. Int J Mol Sci. 2018 Aug 29;19(9):2566. [Content Brief]
- [6]. Qiang LZ, Fang SZ. Telocinobufagin suppresses malignant metastasis of undifferentiated thyroid carcinoma via modulation of the LARP1-mTOR pathway. Kaohsiung J Med Sci. 2025 Mar;41(3):e12934. [Content Brief]
- [7]. Gao Y, et al. Telocinobufagin inhibits the epithelial-mesenchymal transition of breast cancer cells through the phosphoinositide 3-kinase/protein kinase B/extracellular signal-regulated kinase/Snail signaling pathway. Oncol Lett. 2018 May;15(5):7837-7845. [Content Brief]
- [8]. Gao Y, et al. Erratum: Telocinobufagin inhibits the epithelial-to-mesenchymal transition of breast cancer cells through the PI3K/Akt/Snail signaling pathway. Oncol Lett. 2021 Apr;21(4):242. doi: 10.3892/ol.2021.12503. Epub 2021 Jan 31. Erratum for: Oncol Lett. 2018 May;15(5):7837-7845. [Content Brief]
- [9]. Li J, et al. Telocinobufagin, a PLK1 suppressor that inhibits tumor growth and metastasis by modulating CDC25c and CTCF in HNSCC cells. Phytomedicine. 2024 May;127:155440. [Content Brief]
Keywords
